EMERYVILLE, Calif., June 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women’s health and cancer, was one of 275 companies added to the Russell 3000 index today.
Membership in the Russell 3000, which remains in place for one year, means that Bionovo will also be automatically added to the Russell 2000(R) and Russell Microcap, as well as the appropriate growth and style indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
Commenting on the news, Isaac Cohen, CEO of Bionovo, made the following statement: “The company is extremely pleased to be considered for this highly coveted inclusion with the Russell Microcap Index as well as the Russell 3000 Index.” Cohen also added, “This listing is in line with our goals to become more visible and more proactive towards advocating investor relations activities to maximize shareholder value.”
Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world’s best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.
Founded in 1936, Russell is a subsidiary of Northwestern Mutual Life Insurance Company. Headquartered in Tacoma, Wash., U.S., Russell has principal offices in Amsterdam, Auckland, Hong Kong, Johannesburg, London, Melbourne, New York, Paris, San Francisco, Singapore, Sydney, Tokyo and Toronto.
Russell’s indexes are unmanaged and cannot be investing in directly. For more information on Russell indexes, go to http://www.russell.com.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Company Contacts: Bionovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510.420.4180 jim@bionovo.com Media: Katherina Audley Phone: 415.847.7295 katherina.audley@bionovo.com
Bionovo, Inc.
CONTACT: Jim Stapleton, Chief Financial Officer, +1-510-420-4180,jim@bionovo.com, or Media, Katherina Audley, +1-415-847-7295,katherina.audley@bionovo.com, both of Bionovo, Inc.
